RBC Capital: 'What's Regeneron Pharma's (REGN) Best Next Move'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
RBC Capital Reiterates Sector Perform Rating on Regeneron Pharma (REGN)
June 4, 2025 5:09 AM EDTRBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $662.00 price target on Regeneron Pharma (NASDAQ: REGN).
The analyst comments "Our view: In parallel with our report on potential next steps for REGN following the itepekimab setback, we conducted a flash... More
